Special Offer Unlocked Through This Page Only
Get Positioned on the Collecting Side of Slater's Law Before the Billing Starts
Review Biotech Insider for $2,997 $1,997 and get instant access to your Slater's Law research package
Dylan Jovine, Founder and CEO,
Behind the Markets
Thank you for joining me today.
Like I showed you today, one law is now moving through every paycheck in America. Employers are replacing their most expensive line item with machines, and the market rewards them for it within minutes of the wire.
In a single five-day stretch this past January, Amazon, Nike and Home Depot cut 17,575 jobs between them. Every time one of those announcements crossed the wire, the stock went up. This year American employers will pay out roughly $13 trillion in wages, and that money is now changing hands for the fourth time in 236 years. Behind that transfer sits a single company that has filed the paperwork to become the paymaster of the synthetic workforce — for an industry that, by federal rule, can hire from nowhere else.
And on August 7, the company's scheduled software release switched on its AI layer for every customer at once — the largest cutover ever scheduled. This November, its synthetic workers report for their first paid shifts. That is when Wall Street finally gets to see synthetic labor as a billable revenue line.
I've identified the one American company holding the only door into the industry — while Wall Street still has it filed under boring enterprise software, at yesterday's price.
The historical precedents are clear. Micron owned the memory every AI chip needs and rose more than 677% from my recommendation. Palantir was the platform the agencies could not operate without and ran more than 2,800%. And every earlier turn of Slater's Law made ordinary people — a cab driver, an office gofer, a masseuse — rich, in one case multiplying a $1,000 stake more than two thousand times over.
But if you want a shot at the biggest possible gains… you must get positioned before the billing starts.
Please don't wait.
To help you get started, I've prepared a full suite of research briefings telling you everything you need to profit from this once-in-a-generation opportunity.
When you take the next 6 months to try my biotech research service…
You'll get instant access to everything I promised today.
Your Exclusive Membership
Offer Includes
A Full Year of
Twelve Full Investigations a Year$2,997 Value
Biotech Insider is Dylan Jovine's research service covering the companies at the center of medicine, biotechnology and the technology now being built into the drug industry. Each month you receive a new, highest-conviction recommendation with the full investigative case behind it — the same follow-the-money research you've just read, applied to a fresh opportunity.
24/7 Access to
My Model Portfolio
You'll gain access to all current open positions and every closed trade — including recent winners like 449% on Immunogen, 190% on Viking Therapeutics, and 148% on Eli Lilly — so you can get in on every pick still in the buy range.
Instant Access to
The Research Archive
This library includes every past issue and special report ever published — covering biotech, FDA catalysts, drug pipelines, medical technology and the AI now moving into the industry.
Research Updates & Urgent Alerts
You'll get my latest analysis and market intelligence, plus an alert whenever it's time to act — including when it's time to sell. As you've seen, the exit is half the trade.
Professional Customer Support
Our dedicated U.S.-based member services team is available to help with any questions about your subscription, reports, or account.
PLUS YOUR Slater's Law Research Package
The Crown Briefing
The New American Workforce: The One Stock to Ride During the Biggest Wealth Transfer of Our Lifetime
$249 ValueThis is the whole case with a name on it. Page one gives you the company, the ticker and my recommended buy-up-to price. Then the complete evidence trail document by document, my position-sizing guidance, the milestone calendar of every scheduled switch-on and labor-platform date through next year — and the tripwires that would tell me the thesis is weakening, written down before you ever buy.
Bonus Briefing #1
The Checkpoint Stock: The Company Every AI Worker Must Pass Through
$149 ValueSynthetic workers don't drive to an office, but their work still travels across the internet every second of every day — and one company guards the gate all of it has to pass through. I gave my readers this name in May, while the market still files it under plain internet plumbing. The agent traffic it polices is multiplying by the week. This briefing hands you the name, the ticker, and the price I'd pay today.
Bonus Briefing #2
The Landlord of the Genius Factory
$149 ValueThe machine mind that produced more science in a few months than fifty years of the world's best-paid scientists does not belong to itself. It has an owner — a landlord that collects on every discovery those machine minds produce, and paid so little for it that the purchase barely made the news. Wall Street still files that owner under a business with nothing to do with any of it. Inside: the owner of the most productive laboratory of the century, what its machine minds are aimed at next, and my buy-up-to price.
That's at least a $3,544 value for
just $2,997 $1,997 today!
That's just $38.40 per week.
Best of all, you keep everything and risk NOTHING with my ironclad promise to you.
Dylan Jovine's 30-Day Ironclad
100% Money Back Guarantee
If for any reason you decide my service is not for you, no problem! Simply let my team know within 30 days and we'll refund 100% of your subscription fee.
Best of all, the reports are yours to keep no matter what. That's my gift to you for trying out our service.
Dylan Jovine
CEO & Founder
But you must act fast.
Like I showed you today, there are two clocks running against you here. And neither one of them cares what Wall Street believes.
The first clock already fired.
On August 7, the scheduled software release switched the AI layer on for every customer on the platform at once — the largest cutover ever scheduled. The clock still running is November — when the synthetic workers report for their first paid shifts and the billing starts. That date doesn't need Wall Street's permission, and every week you wait, more of the story moves from announcement to line item.
This is not a mega-cap. When the stock runs past our buy-up-to price, I mark it in the portfolio and tell new readers to stand down until it comes back. Earlier is simply better.
If you don't act now, you'll risk being left out.
I believe the simple decision to act today could put you on the collecting side of the machinery instead of the paying side.
So please fill out the easy form below and I'll rush you everything you need to get started today.
Thank you for your time today. I look forward to welcoming you to Biotech Insider.
We have so much to look forward to.
Dylan Jovine
Editor, Biotech Insider